IRIS
SIMONELLI, Matteo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.368
EU - Europa 835
AS - Asia 353
AF - Africa 117
Continente sconosciuto - Info sul continente non disponibili 6
SA - Sud America 5
OC - Oceania 2
Totale 4.686
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.331
FI - Finlandia 220
SG - Singapore 181
IE - Irlanda 161
IT - Italia 126
NG - Nigeria 117
CN - Cina 96
DE - Germania 84
FR - Francia 66
SE - Svezia 63
NL - Olanda 46
CA - Canada 37
GB - Regno Unito 29
TR - Turchia 29
IL - Israele 19
BE - Belgio 16
IN - India 14
CL - Cile 5
EU - Europa 4
IR - Iran 4
PL - Polonia 4
CH - Svizzera 3
CZ - Repubblica Ceca 3
RU - Federazione Russa 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AT - Austria 2
AU - Australia 2
ES - Italia 2
HK - Hong Kong 2
BG - Bulgaria 1
JP - Giappone 1
KR - Corea 1
MD - Moldavia 1
MK - Macedonia 1
NO - Norvegia 1
PH - Filippine 1
PT - Portogallo 1
RO - Romania 1
UA - Ucraina 1
Totale 4.686
Salva come PNG Salva come JPEG
Città #
Wilmington 706
Chandler 508
San Mateo 299
Helsinki 220
Ann Arbor 189
Dublin 161
New York 161
Ashburn 145
Lawrence 127
Princeton 127
Leawood 119
Benin City 117
Singapore 113
Shanghai 87
Woodbridge 81
Boardman 74
Milan 67
Paris 66
Fairfield 60
Phoenix 57
Amsterdam 40
Toronto 35
Kocaeli 29
London 25
San Diego 21
Seattle 21
Brussels 15
Los Angeles 14
Pune 13
Norwalk 12
Santa Clara 9
Abbiategrasso 8
Monmouth Junction 8
Genoa 6
Des Moines 5
Nanjing 5
Redmond 5
Beijing 4
Falkenstein 4
Redwood City 4
Zwolle 4
Brno 3
Cambridge 3
Clearwater 3
Raleigh 3
Taipei 3
Almelo 2
Cupertino 2
Hanover 2
Hong Kong 2
Poznan 2
Sacramento 2
Tappahannock 2
Viterbo 2
Andover 1
Asbest 1
Augusta 1
Berlin 1
Borås 1
Buffalo 1
Chisinau 1
Clifton 1
Everett 1
Falkenberg 1
Gorgonzola 1
Hockessin 1
Indianapolis 1
Jacksonville 1
Kemerovo 1
Köln 1
Laval 1
Leipzig 1
Leuven 1
Manchester 1
Montréal 1
Moscow 1
Newark 1
Niles 1
Nuremberg 1
Pittsfield 1
San Jose 1
Seoul 1
Tehran 1
Torino 1
Valladolid 1
Vienna 1
Warsaw 1
Totale 3.835
Salva come PNG Salva come JPEG
Nome #
Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas 68
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery 66
Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients’ management: close to clinic 62
Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. 57
Role of Myeloid Cells in the Immunosuppressive Microenvironment in Gliomas 57
Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study 57
COVID-19 and liver cancer clinical trials: not everything is lost 56
Response to Sunitinib in an Adult Patient With Rhabdoid Renal Cell Carcinoma 55
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy 55
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme 55
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors 54
Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas 54
Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey 53
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1 in patients with hepatocellular carcinoma 53
Targeted therapy for thymic epithelial tumors: a new horizon ? Review of the literature and two cases reports 52
Multimodal Characterization of Supratentorial Gliomas: Relationship Among Morphological, Metabolic and Molecular features 52
FDG-PET as a tool to optimize residual surgery in patients with primary extragonadal germ cell tumors: preliminary results 52
Changes in shedding of soluble tumor necrosis factor receptors (sR1/R2) and in dynamic MRI as early predictors of outcome with NGR-hTNF 52
Thymoma associated with myasthenia and autonomic anti-Hu paraneoplastic neuropathy 51
Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top" 51
Pathological characterization of nivolumab –related liver injury in a patient with glioblastoma 50
Advances in the biology of malignant pleural mesothelioma 50
Correlation of microvascular fractal dimension with positron emission tomography [C-11]-methionine uptake in glioblastoma multiforme: Preliminary findings 49
Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma 49
Reproducibility of the WHO classification of thymomas: practical implications 49
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 49
Infertility risk and teratogenicity of molecular targeted anticancer therapy: a challenging issue 48
Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma 48
Expression of the transcription factor HEY1 in glioblastoma: a preliminary clinical study 48
Conducting Phase I Trials During the SARS-Coronavirus-2 Outbreak: About Science and Care 48
High-grade gliomas (HGGs) and immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience 47
Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in a observational study 47
Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study. 47
HIGH-GRADE GLIOMAS AND IMMUNOTHERAPEUTIC EARLY PHASE CLINICAL TRIALS: A SINGLE-CENTER EXPERIENCE 47
The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing 47
Neutrophils in Gliomas 45
Prognostic and predictive role of [F-18]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy 45
Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives 45
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 44
Electrolyte abnormalities and side effects of zoledronate in patients with bone metastases 44
Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin 44
COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report 44
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 43
Insulin-Like Growth Factor-1 Receptor and Phosphorylated AKT-Serine 473 Expression in 132 Resected Thymomas and Thymic Carcinomas 43
Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment 42
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study 42
Is supratotal resection achievable in low-grade gliomas? Feasibility, putative factors, safety, and functional outcome 41
Editorial for "Noninvasive Assessment of MGMT Promoter Methylation Status in World Health Organization Grade II-IV Glioma Using Histogram Analysis of Inflow-Based Vascular-Space Occupancy Combined with Structural MR Imaging" 41
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma 41
Herpes infections in breast cancer patients treated with adjuvant chemotherapy 40
Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma 40
Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis 40
The Role of Pemetrexed in the Pharmacotherapy of Malignant Pleural Mesothelioma 39
HYPOFRACTIONATED RADIATION THERAPY (OVER 3 WEEKS) CAN REPLACE CONVENTIONAL RADIATION THERAPY SCHEDULE (OVER 6 WEEKS) IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS? THE TIMES ARE RIPE 39
VINORELBINE (V) IN PEMETREXED-PRETREATED PATIENTS (PTS) WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 38
Lower Grade Gliomas: Relationships Between Metabolic and Structural Imaging with Grading and Molecular Factors 38
Value of Surgical Resection in Patients with Newly Diagnosed Grade III Glioma Treated in a Multimodal Approach: Surgery, Chemotherapy and Radiotherapy 38
Imaging biomarkers in primary brain tumours 38
Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution 37
Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review. 37
Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO) 37
Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series 36
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal 36
Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations 35
Supratotal resection in newly diagnosed GBMs: role of this surgical strategy beyond enhancing boundaries 35
Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors 35
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma 34
Outcome evaluation of patients with diagnosed WHO grade III glioma treated according to the molecular profile, the hystology, and the extent of resection (EOR) 34
Three-day low-dose Cisplatin administration in advanced non-small cell lung cancer (NSCLC): Efficacy and reduced toxicity 34
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 34
THE ROLE OF THYMIDTYLATE SYNTHASE (TS) AND EXCISION REPAIR CROSS-COMPLEMENTING GROUP 1 (ERCC1) IMMUNOHISTOCHEMICAL EXPRESSION IN MALIGNANT PLEURAL MESOTHELIOMA (MPM) PATIENTS TREATED WITH PEMETREXED AND CARBOPLATIN 34
Pharmacodynamic (PD) evaluation of soluble proteins from a phase I trial of lapatinib (L) in combination with sorafenib (S) 34
High incidence of hypocalcemia in patients with bone metastases from different kinds of neoplasms, treated with zoledronate 33
Future developments in the management of malignant pleural mesothelioma 33
Reliability of the HER2 status assessment by immunohistochemistry for breast cancer patients after preoperative chemotherapy 33
Primary ovarian insufficiency associated with pazopanib therapy in a breast angiosarcoma patient A CARE-compliant case report 33
Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience 32
PHASE I AND PHARMACODYNAMIC STUDY OF NGR-HTNF ADMINISTERED AT HIGH DOSES IN REFRACTORY PATIENTS WITH SOLID TUMORS 32
Vinorelbine as second or third-line therapy in pemetrexed-pretreated malignant pleural mesothelioma (MPM) patients 32
Optimizing residual surgery for patients with primary extragonadal germ cell tumors 31
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 31
Newly diagnoses grade III glioma patients: evaluation of factors conditioning outcome 31
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors 31
Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis 31
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study 30
Phase I study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC) 30
High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: a critical review 30
Outcome of high-grade gliomas (HGGs) treated into immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience 29
Retreatment with pemetrexed-based chemotherapy (PBC) in patients with malignant pleural mesothelioma (MPM): An observational study 29
IMPACT OF SOLUBLE TUMOR NECROSIS FACTOR-RECEPTORS (STNF-RS) SHEDDING ON OUTCOME IN PATIENTS TREATED WITH NGR-HTNF 29
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours 29
Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma: results of phase I trial 29
Phase I, Pharmacokinetics (PK), Pharmacodynamic (PD) Study of Lapatinib (L) in Combination With Sorafenib (S) in Patients With Advanced Refractory Solid Tumours 29
IS SURGICAL RESECTION USEFUL IN ELDERLY NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS? OUTCOME EVALUATION AND PROGNOSTIC FACTORS ASSESMENT 28
Phase II study of hypofractionated radiation therapy with concomitant and adjuvant Temozolomide following surgical resection for patients with newly diagnosed glioblastoma:preliminary evaluation 28
Vinorelbine as Second or Third-Line Therapy in Pemetrexed-Pretreated Malignant Pleural Mesothelioma (MPM) Patients 28
Phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) trial of NGR-hTNF given at high doses in patients with refractory solid tumors 28
Final results from ARQ 197-114: A phase 1b safety trial evaluating ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC) 28
Phase Lib trial of tivantinib in combination with carboplatin and pernetrexed as first-line treatment in patients (pts) with advanced nonsquamous NSCLC or malignant pleural mesotheliorna (MPM) 26
PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB PLUS PEMETREXED AND CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 26
Totale 4.120
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.476
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.476
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202044 0 0 0 0 0 0 0 0 0 0 1 43
2020/20211.426 47 10 19 8 11 395 184 99 281 185 17 170
2021/2022689 32 5 13 139 4 6 28 102 55 71 199 35
2022/20231.535 285 66 162 148 120 99 3 119 261 153 106 13
2023/20241.111 58 108 169 39 45 248 88 50 11 32 109 154
2024/202512 12 0 0 0 0 0 0 0 0 0 0 0
Totale 4.817